Home    Back

96. Crohn disease
2,209 clinical trials,   1,276 drugs   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
5 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2007-000189-19-IT
(EUCTR)		10/06/200817/10/2008Multicenter, randomized, double-blind, placebo-controlled, study to evaluate the effect of ITF2357 on mucosal healing in patients with moderate-to-severe active Crohn?s Disease - DSC/06/2357/23Multicenter, randomized, double-blind, placebo-controlled, study to evaluate the effect of ITF2357 on mucosal healing in patients with moderate-to-severe active Crohn?s Disease - DSC/06/2357/23 Crohn's disease
MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease		Product Name: ITF 2357ITALFARMACONULLNot RecruitingFemale: yes
Male: yes		80Netherlands;Belgium;Italy
2NCT00792740
(ClinicalTrials.gov)		October 200714/11/2008Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's DiseaseMulticenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's DiseaseCrohn's DiseaseDrug: ITF2357;Drug: Placebo capsulesItalfarmacoNULLTerminated18 Years88 YearsBoth51Phase 1;Phase 2Belgium
3EUCTR2007-000189-19-BE
(EUCTR)		16/08/200703/08/2007Multicenter, randomized, double-blind, placebo-controlled study to evaluate the effect of ITF2357 on mucosal healing in patients with moderate-to-severe active Crohn’s DiseaseMulticenter, randomized, double-blind, placebo-controlled study to evaluate the effect of ITF2357 on mucosal healing in patients with moderate-to-severe active Crohn’s Disease Moderate-to-severe active Crohn’s Disease
MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease		Product Code: ITF2357Italfarmaco S.p.A.NULLNot RecruitingFemale: yes
Male: yes		80Netherlands;Belgium;Italy
4EUCTR2007-000189-19-NL
(EUCTR)		06/08/200714/06/2007Multicenter, randomized, double-blind, placebo-controlled study to evaluate the effect of ITF2357 on mucosal healing in patients with moderate-to-severe active Crohn’s DiseaseMulticenter, randomized, double-blind, placebo-controlled study to evaluate the effect of ITF2357 on mucosal healing in patients with moderate-to-severe active Crohn’s Disease Moderate-to-severe active Crohn’s Disease
MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease		Product Code: ITF2357Italfarmaco S.p.A.NULLNot RecruitingFemale: yes
Male: yes		80Netherlands;Belgium;Italy
5EUCTR2004-004854-19-SK
(EUCTR)		25/04/200509/02/2005A randomized, double-blind, placebo-controlled, parallel group multicenter study to investigate efficacy and safety of ITF 2357 in the management of patients with active moderate to severe Crohn’s diseaseA randomized, double-blind, placebo-controlled, parallel group multicenter study to investigate efficacy and safety of ITF 2357 in the management of patients with active moderate to severe Crohn’s disease Crohn's diseaseProduct Name: ITF2357
Other descriptive name: Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphtalen-2-ylmethyl]-ammonium chloride mon		Italfarmaco S.p.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		50Phase 2Slovakia

Back to top